Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1953 2
1955 2
1956 1
1957 1
1959 1
1961 7
1962 5
1963 6
1964 7
1965 9
1966 5
1967 15
1968 8
1969 7
1970 7
1971 4
1972 4
1973 8
1974 2
1975 3
1976 11
1977 6
1978 8
1979 17
1980 24
1981 8
1982 20
1983 24
1984 23
1985 33
1986 26
1987 27
1988 18
1989 34
1990 40
1991 21
1992 37
1993 34
1994 36
1995 54
1996 41
1997 42
1998 50
1999 54
2000 45
2001 47
2002 56
2003 67
2004 66
2005 59
2006 85
2007 95
2008 99
2009 118
2010 142
2011 144
2012 145
2013 145
2014 174
2015 172
2016 147
2017 136
2018 177
2019 176
2020 205
2021 177
2022 179
2023 146
2024 143
2025 153
2026 70

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,739 results

Results by year

Filters applied: . Clear all
Page 1
Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease.
Sawamoto N, Doi D, Nakanishi E, Sawamura M, Kikuchi T, Yamakado H, Taruno Y, Shima A, Fushimi Y, Okada T, Kikuchi T, Morizane A, Hiramatsu S, Anazawa T, Shindo T, Ueno K, Morita S, Arakawa Y, Nakamoto Y, Miyamoto S, Takahashi R, Takahashi J. Sawamoto N, et al. Among authors: morita s. Nature. 2025 May;641(8064):971-977. doi: 10.1038/s41586-025-08700-0. Epub 2025 Apr 16. Nature. 2025. PMID: 40240591 Free PMC article. Clinical Trial.
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H. Tsukita Y, et al. Among authors: morita s. JAMA Oncol. 2024 Apr 1;10(4):439-447. doi: 10.1001/jamaoncol.2023.6277. JAMA Oncol. 2024. PMID: 38451530 Free PMC article.
CRISPR/Cas9.
Hatada I, Morita S, Horii T. Hatada I, et al. Among authors: morita s. Methods Mol Biol. 2023;2637:41-47. doi: 10.1007/978-1-0716-3016-7_3. Methods Mol Biol. 2023. PMID: 36773136
Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes.
Lei PJ, Pereira ER, Andersson P, Amoozgar Z, Van Wijnbergen JW, O'Melia MJ, Zhou H, Chatterjee S, Ho WW, Posada JM, Kumar AS, Morita S, Menzel L, Chung C, Ergin I, Jones D, Huang P, Beyaz S, Padera TP. Lei PJ, et al. Among authors: morita s. J Exp Med. 2023 Sep 4;220(9):e20221847. doi: 10.1084/jem.20221847. Epub 2023 Jun 21. J Exp Med. 2023. PMID: 37341991 Free PMC article.
Cancer tissue of origin constrains the growth and metabolism of metastases.
Sivanand S, Gultekin Y, Winter PS, Vermeulen SY, Tchourine KM, Abbott KL, Danai LV, Gourgue F, Do BT, Crowder K, Kunchok T, Lau AN, Darnell AM, Jefferson A, Morita S, Duda DG, Aguirre AJ, Wolpin BM, Henning N, Spanoudaki V, Maiorino L, Irvine DJ, Yilmaz OH, Lewis CA, Vitkup D, Shalek AK, Vander Heiden MG. Sivanand S, et al. Among authors: morita s. Nat Metab. 2024 Sep;6(9):1668-1681. doi: 10.1038/s42255-024-01105-9. Epub 2024 Aug 19. Nat Metab. 2024. PMID: 39160333 Free PMC article.
Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Morita S, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y, Takeuchi O. Yaku A, et al. Among authors: morita s. Circulation. 2022 Sep 27;146(13):1006-1022. doi: 10.1161/CIRCULATIONAHA.122.059435. Epub 2022 Aug 23. Circulation. 2022. PMID: 35997026
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.
Ueno T, Chow LWC, Han W, Huang CS, Mann GB, Morita S, Haga H, Fakhrejahani E, Kobayashi T, Bando H, Inoue K, Tokiwa M, Suwa H, Aruga T, Minamiguchi S, Yamada Y, Tanabe Y, Takada M, Yamashita T, Iwata H, Chung CF, Takahara S, Tokunaga E, Imoto S, Lee ES, Sagara Y, Kim JH, DeBoer RH, Kim HA, Lai HW, Hou MF, White M, Umeyama Y, Toi M. Ueno T, et al. Among authors: morita s. Endocr Relat Cancer. 2025 Sep 11;32(9):e240353. doi: 10.1530/ERC-24-0353. Print 2025 Sep 1. Endocr Relat Cancer. 2025. PMID: 40888443 Free PMC article. Clinical Trial.
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).
Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, Sugimoto N, Minashi K, Imano M, Inamoto R, Kodera Y, Kume H, Yamaguchi K, Hashimoto W, Muro K; EN-DEAVOR Study Group. Kawakami H, et al. Among authors: morita s. Gastric Cancer. 2025 Jan;28(1):51-61. doi: 10.1007/s10120-024-01555-w. Epub 2024 Oct 10. Gastric Cancer. 2025. PMID: 39387986 Free PMC article.
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
Yamamoto Y, Iwata H, Saji S, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Taira N, Morita S, Toi M, Ohno S, Masuda N. Yamamoto Y, et al. Among authors: morita s. J Clin Oncol. 2025 May 10;43(14):1631-1637. doi: 10.1200/JCO-24-01673. Epub 2025 Jan 24. J Clin Oncol. 2025. PMID: 39854662 Free PMC article. Clinical Trial.
3,739 results